IL17A and metabolic dysfunction-associated steatotic liver disease: The AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) pathway was reported to be suppressed in diabetic mice, potentially reducing hepatic macrophage autophagy and increasing IL-17/IL-23 axis-related molecules’ expression, contributing to liver injury in T2DM with NAFLD [26] (Table 1).